ArticleInternational journal of genomics2026
USP44 Stabilizes MAOB via Deubiquitination to Inhibit Cisplatin Resistance in Lung Adenocarcinoma.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- USP44 Stabilizes MAOB via Deubiquitination to Inhibit Cisplatin Resistance in Lung Adenocarcinoma.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin (DDP), as a commonly used chemotherapeutic agent for the clinical treatment of lung adenocarcinoma (LUAD), serves a key function in suppressing tumor progression; however, the development of tumor cell resistance has restricted its clinical application. Methods: Differentially expressed genes (DEGs) between A549 and A549-DDP cells in the GEO dataset (GSE157692) were analyzed, and DDP resistance-related targets were downloaded from GeneCards; candidate genes were obtained via their intersection. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were conducted on candidate genes. Subsequently, key gene expression was analyzed via GEPIA and TCGA databases and verified by Western blot. Cell proliferation, apoptosis, migration, and invasion were detected by CCK-8, colony formation, flow cytometry, and Transwell assays. The interaction between MAOB and USP44 was predicted by UbiBrowser, and their regulatory relationship was validated using coimmunoprecipitation (Co-IP) and cycloheximide (CHX) chase assays. Results: Monoamine oxidase B (MAOB) was identified as a core target. MAOB showed reduced expression in DDP-resistant LUAD cells and tumor tissues, with low levels linked to worse prognosis. MAOB overexpression enhanced DDP sensitivity, repressed cell proliferation/migration/invasion, promoted apoptosis, and reversed epithelial-mesenchymal transition (EMT). Ubiquitin-specific protease 44 (USP44) was downregulated in DDP-resistant LUAD models and stabilized MAOB via deubiquitination. MAOB knockdown reversed USP44 overexpression's effects on DDP resistance and malignant phenotypes. Conclusion: USP44 promoted MAOB protein stability via deubiquitination, and the USP44-MAOB axis inhibited DDP resistance and malignant phenotypes of LUAD cells. This axis is thus a potential therapeutic target for improving DDP resistance in LUAD, providing a new direction for clinical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.